Clinical Trials
9 trialsNCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00308165 2025-06-27
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Columbia University
Phase 1 Completed
NCT00638898 2025-03-20
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Phase 1 Completed
NCT00003372 2020-04-08
Topotecan in Treating Patients With Recurrent Brain Tumors
Canadian Cancer Trials Group
Phase 2 Completed
NCT00918320 2016-01-26
TOTEM2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT00610571 2013-10-25
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Duke University
Phase 1 Completed
NCT00002986 2013-02-20
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT00002814 2011-10-27
Combination Chemotherapy for Patients With Brain Cancer
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00541138 2011-09-21
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
City of Hope Medical Center
Phase 2 Completed